Skin Conditions, Psoriasis and Eczema, Personal Care Treatments Archives

Posted on: July 16, 2023July 29, 2023

MZL – Emzaloid™ Delivery System

Meyer Zall Laboratories Emzaloid Delivery System

Meyer Zall Laboratories developed the Emzaloid™ “Biomaterial Active Ingredient Delivery System”. The MZL Emzaloid™ Technology is a patented trans dermal drug delivery system comprising of a unique submicron emulsion type formulation capable of encapsulating various drugs and delivering these with high efficacy to target sites in the body. The size, shape and clustering of Emzaloid™ in “sponges” and in so-called “depots” can be controlled and reproduced through mechanical composition and other means. The absorption capabilities of the Emzaloid™ can be controlled in this manner.

The encapsulation of actives within the Emzaloid™ Technology creates a safer and more effective formulation than one involving the said active alone.

Whilst there are many existing delivery system technologies such as lipids or viral vectors, the Emzaloid™ Technology is unique among these in that it is comprised of essential substances which are natural ingredients of the human body. These substances are treated in a special manner which may afford significant advantages over other delivery systems. Emzaloid™ is significantly different from liposome and nanosome delivery systems.

Since the very beginning, the effectiveness of the topical Linotar / Exorex product was beyond reasonable expectations and it displayed an exceedingly high rate of successful treatment. Linotar / Exorex contains the active agent coal tar which is commonly used in the treatment of Psoriasis. This led the scientists to realise that the Linotar / Exorex formulation was more than simply a new generation cosmetically acceptable coal tar product.

Reference

Saunders James C J, Davis Henry J, Coetzee Linda, Botha Susan; Kruger Ansie E, Grobler, Anne. A Novel Skin Penetration Enhancer: Evaluation By Membrane Diffusion And Confocal Microscopy. J Pharm Pharmaceut Sci (https://www.cspscanada.org/) 2(3):99-107, 1999.

Web Links

Exorex / Linotar trans dermal carrier: https://sites.ualberta.ca/~csps/JPPS2(3)/J.Saunders/microscopy.htm

TECHNOLOGY

Posted on: September 1, 2021July 29, 2023

Clinical Success

Clinical experience has shown that Exorex® (Linotar®) is a safe, effective and cosmetically acceptable treatment for psoriasis.
More than 700 patients have been enrolled in controlled clinical trials.
There has been more than 16 million patient days of usage over the last 9 years.
The unique delivery system ensures an effective transdermal carrier of coal tar.
Exorex® (Linotar®) is approved in more than 10 countries around the world.

临床实验成功

•临床实验证明Exorex是一种安全，有效和美容上可接受的治疗牛皮癣产品。
•超过700位患者已注册参加临床对照试验。
•在过去9年已经有超过1600万患者使用。
•独特的输送系统，确保煤焦油的透皮载体高度有效。
•Exorex®(Linotar®)在全球10多个国家被核准。

Posted on: September 1, 2021July 29, 2023

Linotar / Key Benefits

The Linotar® Range Treatment System has been especially developed to control the symptoms of psoriasis and eczema.

The success of Linotar® is based on a unique trans dermal delivery system containing a mixture of natural essential fatty acids first identified from the skin of the banana.

This unique base:

See John’s Story…

8 Key benefits:

Clinically proven to control the symptoms of psoriasis.
Easily applied and quickly absorbed into the skin.
Colorless and virtually odorless after proper application.
Contains NO cortisones.
NO side-effects observed as are often associated with other treatments.
Will not stain clothing when properly applied.
No evidence that resistance to the product occurs.
The full range of Linotar® Gel 1% and the compatible Linocream® Moisturising Cream and Linoscalp® leave-in Scalp Conditioner ensures a complete body treatment.